Brief: Vidac Pharma Starts Phase 2B Trial for Targeted Actinic Keratosis Treatment
11/12/2025 11:40
Dec 11 (Reuters) - Vidac Pharma Holding PLC T9G.SG: VIDAC PHARMA HOLDING: INITIATES PHASE 2B CLINICAL TRIAL FOR HIGHLY PROLIFERATIVE ACTINIC KERATOSIS LESIONS TARGETED TREATMENT Further company coverage: T9G.SG ((((Reuters.Briefs@thomsonreuters.com));))